In addition, it has been reported that RhoGDI could stimulate the transcriptional activity of estrogen receptor α(ERα) via a RhoGTPase-dependent pathway that acts on estrogen receptor co-activators GRIP1 and CBP/p300 in breast cancer [18]. Here, GRIP1 is linked to breast carcinoma.